HealthCare Royalty Partners is a global investment firm that partners with healthcare companies, non-profit institutions and inventors.
We are a $3.0+ billion global healthcare investment firm. We invest primarily in commercial stage healthcare product assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, our senior investment team has completed more than 60 royalty investments valued in excess of $2.5 billion. For more information, visit www.healthcareroyalty.com.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 30, 2022
Ardelyx
|
Post-IPO Debt | $20M | Biotechnology | Yes |
Feb 12, 2014
Nuron Biotech
|
Private Equity(PE) | $22.70M | Biotechnology | — |
Dec 26, 2012
Nuron Biotech
|
Private Equity(PE) | $80M | Biotechnology | Yes |